- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Innovotech Inc: Innovotech loses $655,700 in Q2 | 1 | Stockwatch | ||
| 18.08. | Innovotech Inc. Reports Q2 2026 Financial Results | 2 | TheNewswire | ||
| 14.08. | Innovotech Inc. Launches of InnovoTEST Hazardous Drug Wipe Testing Kits to Support Pharmacy Compliance and Healthcare Worker Safety | 2 | TheNewswire | ||
| 16.06. | Innovotech Inc. Announces CFO Transition and Reports 2026 Annual General Meeting Result | 2 | TheNewswire | ||
| 14.05. | Innovotech Inc. Receives Support to Develop Antimicrobial Testing Services and Product Enhancements | 2 | TheNewswire | ||
| 12.05. | Innovotech Inc. Reports Q1 2026 Financial Results and Operational Update | 1 | TheNewswire | ||
| 12.05. | Innovotech reports Q1 results | 1 | Seeking Alpha | ||
| INNOVOTECH Aktie jetzt für 0€ handeln | |||||
| 30.04. | Fendx Technologies Inc (2): Fendx hires Innovotech for Foley regulatory pathway | 8 | Stockwatch | ||
| 30.04. | FendX Technologies Inc.: FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program | 1.138 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection... ► Artikel lesen | |
| 15.04. | Innovotech Inc. Begins Trading on OTCQB Under Symbol IOTCF, Expanding Access for U.S. Investors | 1 | TheNewswire | ||
| 01.04. | Innovotech Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results | 1 | TheNewswire | ||
| 26.01. | DealFlow Events: Innovotech Inc. Presenting at the 3rd Annual DealFlow Discovery Conference | 359 | ACCESS Newswire | EDMONTON, AB / ACCESS Newswire / January 26, 2026 / Innovotech Inc. (TSXV:IOT), a leading contract research organization providing proprietary antimicrobial testing and advanced laboratory services... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 17,130 | 0,00 % | Summit Therapeutics Stock Rises 11% | ||
| ALUMIS | 11,360 | 0,00 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| CG ONCOLOGY | 74,33 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,950 | 0,00 % | Dyne to present preclinical data on four DMD therapies | ||
| CLIMB BIO | 14,590 | 0,00 % | Climb Bio, Inc.: Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy | ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 12,750 | -0,23 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 37,470 | -1,80 % | QIAGEN N.V.: QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction | New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety Builds on more than 3... ► Artikel lesen | |
| ERASCA | 16,260 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,950 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 59,64 | -0,02 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 355,10 | -0,01 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RELAY THERAPEUTICS | 19,010 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,18 | -0,09 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| AMYLYX PHARMACEUTICALS | 33,975 | 0,00 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? | ||
| IMMUNOVANT | 39,110 | -0,03 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen |
Das Unternehmen INNOVOTECH INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNOVOTECH INC finden Sie auf Wallstreet Online.